Barclays PLC Akero Therapeutics, Inc. Transaction History

Barclays PLC

$436 Billion
Q2 2025

A detailed history of Barclays PLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 533,416 shares of AKRO stock, worth $28.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

533,416

Previous 533,416 -0.0%

Holding current value

$28.8 Million

Previous $28.5 Million -0.0%

% of portfolio

0.01%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$34.04 - $56.28 $14 Million - $23.1 Million	410,253 Added 333.1%	533,416 $28.5 Million
Q1 2025 May 15, 2025	SELL	$21.87 - $57.56 $211,570 - $556,835	-9,674 Reduced 7.28%	123,163 $4.99 Million
Q4 2024 Feb 13, 2025	BUY	$26.75 - $35.28 $138,270 - $182,362	5,169 Added 4.05%	132,837 $3.7 Million
Q3 2024 Nov 15, 2024	BUY	$21.45 - $29.34 $1.54 Million - $2.1 Million	71,652 Added 127.91%	127,668 $3.66 Million
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $268,516 - $361,052	-14,665 Reduced 20.75%	56,016 $1.32 Million
Q1 2024 May 15, 2024	SELL	$17.76 - $31.18 $3.12 Million - $5.47 Million	-175,593 Reduced 71.3%	70,681 $1.79 Million
Q4 2023 Feb 15, 2024	BUY	$11.38 - $50.33 $1.31 Million - $5.78 Million	114,828 Added 87.36%	246,274 $5.75 Million
Q3 2023 Nov 07, 2023	SELL	$41.19 - $52.25 $479,122 - $607,772	-11,632 Reduced 8.13%	131,446 $6.65 Million
Q2 2023 Aug 03, 2023	BUY	$36.89 - $56.88 $2.43 Million - $3.75 Million	65,854 Added 85.28%	143,078 $6.68 Million
Q1 2023 May 04, 2023	SELL	$37.27 - $50.24 $981,244 - $1.32 Million	-26,328 Reduced 25.42%	77,224 $2.95 Million
Q4 2022 Feb 13, 2023	BUY	$33.44 - $54.8 $3.42 Million - $5.61 Million	102,364 Added 8616.5%	103,552 $5.67 Million
Q3 2022 Nov 03, 2022	SELL	$10.15 - $34.05 $110,533 - $370,804	-10,890 Reduced 90.16%	1,188 $40,000
Q2 2022 Aug 12, 2022	BUY	$8.0 - $15.01 $35,744 - $67,064	4,468 Added 58.71%	12,078 $114,000
Q1 2022 May 16, 2022	SELL	$12.97 - $22.26 $360,825 - $619,273	-27,820 Reduced 78.52%	7,610 $107,000
Q4 2021 Feb 14, 2022	BUY	$19.87 - $26.24 $424,462 - $560,538	21,362 Added 151.85%	35,430 $749,000
Q3 2021 Nov 09, 2021	BUY	$18.65 - $25.46 $160,240 - $218,752	8,592 Added 156.9%	14,068 $315,000
Q2 2021 Aug 13, 2021	SELL	$24.81 - $32.35 $180,641 - $235,540	-7,281 Reduced 57.07%	5,476 $136,000
Q1 2021 May 13, 2021	BUY	$24.04 - $34.19 $163,928 - $233,141	6,819 Added 114.84%	12,757 $369,000
Q4 2020 Feb 11, 2021	SELL	$25.12 - $29.89 $56,042 - $66,684	-2,231 Reduced 27.31%	5,938 $153,000
Q3 2020 Nov 12, 2020	SELL	$30.79 - $39.92 $284,191 - $368,461	-9,230 Reduced 53.05%	8,169 $252,000
Q2 2020 Aug 12, 2020	BUY	$19.25 - $26.76 $281,377 - $391,150	14,617 Added 525.41%	17,399 $434,000
Q1 2020 May 13, 2020	SELL	$12.8 - $27.05 $28,620 - $60,483	-2,236 Reduced 44.56%	2,782 $59,000
Q4 2019 Feb 10, 2020	BUY	$17.37 - $27.27 $41,010 - $64,384	2,361 Added 88.86%	5,018 $112,000
Q3 2019 Nov 14, 2019	BUY	$16.89 - $29.88 $44,876 - $79,391	2,657 New	2,657 $61,000

Others Institutions Holding AKRO

# of Institutions

298

Shares Held

92.4M

Call Options Held

1.72M

Put Options Held

901K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.5B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account